The nature and implementation expectations of the tripartite Partnership between MSM, TU, and UAB CCC lends itself to a mixed-method, triangulated, formal evaluation plan, using both quantitative and qualitative data. Evaluation will be continuous throughout the grant period (years 1-5) in order to allow for ongoing activity review and quality control. Two critical issues must be determined: (a) the success and progress of the planned activities;and (b) if the specific issues of project performance and evaluation questions are being addressed. For these institutions, these processes began with the U56 and P20 grants and have continued under the U54 mechanism. Drs. Scarinci and Martin (evaluation co-leaders) and the evaluation committee will be responsible for the overall evaluation of the program. They, in turn, will make recommendations, and the actions will be the responsibility of the Principal Investigators at each partner institution and will be accomplished administratively with the advice, guidance, and direction of the Partnership Internal Advisory Committee (lAC), Partnership Advisory Council (PAC) and the Program Steering Committee (PSC). These three groups (see description below) will provide the planning and evaluation for the Partnership activities that are designed to achieve the goals and objectives ofthe Partnership (see the Overall Objectives and Partnership Integration Section). The Partnership Administrative Core, which is ultimately responsible for planning and evaluation of Partnership-wide activities and progress, is comprised of the Internal Advisory Committee (lAC), the Partnership Advisory Council (PAC), and the Program Steering Committee (PSC). The lAC is responsible for internal planning, execution, and evaluation ofthe Partnership;the PAC reviews its decisions and provides guidance in an intra-institutional context;and the PSC functions as the external review and evaluation component

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Moore, Justin Xavier; Royston, Kendra J; Langston, Marvin E et al. (2018) Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control :
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Piyathilake, Chandrika J; Badiga, Suguna; Borak, Samuel G et al. (2017) A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Womens Health 9:413-420
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Jia, Xu; Shanmugam, Chandrakumar; Paluri, Ravi K et al. (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198-20212
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 193 publications